Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Pernix Theraptcs (PTX)

Pernix Theraptcs (PTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Pernix Theraptcs 10 NORTH PARK PLACE SUITE 201 MORRISTOWN NJ 07960 USA

www.pernixtx.com P: 800-793-2145

Description:

Pernix Therapeutics Holdings Inc., formerly known as Golf Trust of America, Inc., is a specialty pharmaceutical company focused on developing and commercializing pharmaceutical products to meet medical needs primarily in pediatrics. The Company's product families include Aldex, Pediatex, Z-Cof, Brovex, ReZyst and QuinZyme. Its ALDEX products are indicated for the treatment of allergies and symptoms of the common cold. PEDIATEX TD is for the treatment of respiratory allergies. Z-COF 8DM is for the treatment of allergies and symptoms of the common cold. The BROVEX products are indicated for the treatment of allergies and symptoms of the common cold. REZYST IM is a chewable tablet probiotic indicated to replace active cultures that are destroyed by diet and antibiotics and to reduce symptoms associated with irritable bowel syndrome and various gastrointestinal issues. QUINZYME is a dissolve tablet for patients with depleted ubiquinone levels and for patients on statin therapy. Pernix is based in Magnolia, Texas.

Key Statistics

Overview:

Market Capitalization, $K 3,046
Shares Outstanding, K 14,506
Annual Sales, $ 146,070 K
Annual Net Income, $ -77,140 K
Last Quarter Sales, $ 37,160 K
Last Quarter Net Income, $ -11,850 K
60-Month Beta 1.20
% of Insider Shareholders 1.30%
% of Institutional Shareholders 20.43%

Growth:

1-Year Return -92.76%
3-Year Return -98.77%
5-Year Return -99.40%
5-Year Revenue Growth 138.25%
5-Year Earnings Growth -2,633.33%
5-Year Dividend Growth 0.00%

Per-Share Information:

Next Earnings Date 03/14/19
Earnings Per Share ttm -6.37
EPS Growth vs. Prev Qtr 21.24%
EPS Growth vs. Prev Year -56.14%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Most Recent Dividend 0.250 on 08/21/01
Dividend Payable Date 09/07/01
Dividend Payout Ratio 0.00%
Most Recent Split 1-10 on 10/14/16

PTX Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % 0.00%
Return-on-Assets % -37.01%
Profit Margin % -52.81%
Debt/Equity N/A
Price/Sales 0.02
Price/Cash Flow N/A
Price/Book N/A
Book Value/Share -12.38
Interest Coverage -1.08
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar